Syntara Limited (ASX:SNT) Addresses ASX Price Query
Syntara Limited addresses recent trading activity and plans to present interim data at the ASH Meeting.
Syntara Limited addresses recent trading activity and plans to present interim data at the ASH Meeting.
Alpha HPA Limited updates on project milestones and market developments across its HPA First Project and product offerings.
Anatara Lifesciences updates on its GaRP-IBS trial with promising recruitment numbers and anticipates results in early 2025.
4DMedical Limited (ASX:4DX) presents its innovative CT:VQ technology at RSNA 2024, poised to revolutionise lung health diagnostics.
Cynata Therapeutics Limited (ASX:CYP) has announced a trading halt pending a significant clinical trial update.
Acrux Limited has received FDA approval for Nitroglycerin Ointment, expanding its portfolio in the topical market.
Pro Medicus co-founders Dr Sam Hupert and Mr Anthony Hall sell shares, reaffirming their commitment and retaining significant holdings.
Black Dragon Gold faces permitting delays as its land re-zoning application for the Salave Gold Project is rejected by local council.
4DMedical Limited announces a contract with Perth Radiological Clinic to enhance lung diagnostics using XV Technology across multiple clinics.
Athena Resources (ASX:AHN) announces a fully underwritten A$2.67 million entitlement offer to fund its Byro Magnetite Project.